Jacqueline Hayes, MD
Family Medicine · Saint Louis, MONPI 1134275662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 284 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,964 and has fallen 83.3% since, to $328 in 2025.
Across 284 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$840
- Pfizer$609
- Novo Nordisk$539
- Lilly USA, LLC$415
- Novartis$300
- Takeda Pharmaceuticals U.S.A., Inc.$227
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,950100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $840 |
| Pfizer | 38 | $609 |
| Novo Nordisk | 32 | $539 |
| Lilly USA, LLC | 20 | $415 |
| Novartis | 17 | $300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $227 |
| GSK | 13 | $206 |
| Merck | 12 | $195 |
| Abbott | 11 | $192 |
| AstraZeneca | 12 | $174 |
| Amgen | 9 | $150 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $149 |
| Otsuka America Pharmaceutical, Inc. | 6 | $106 |
| Exact Sciences | 5 | $89 |
| Bayer | 5 | $74 |
| Idorsia Pharmaceuticals US Inc | 5 | $73 |
| Vanda Pharmaceuticals Inc. | 4 | $57 |
| Sumitomo Pharma America, Inc. | 3 | $53 |
| Dexcom, Inc. | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Optinose US, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Viiv Healthcare Company | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$4,950 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $79,851 |
| EliquisApixaban | 64 | $62,158 |
| JardianceEmpagliflozin | 32 | $48,871 |
| TrulicityDulaglutide | 35 | $46,598 |
| MounjaroTirzepatide | 34 | $46,069 |
| RybelsusSemaglutide | 25 | $38,953 |
| Spiriva RespimatTiotropium Bromide | 16 | $7,954 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $5,486 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,021 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 17 | $4,636 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $4,217 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,911 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $3,010 |
| Bupropion XlBupropion Hcl | 36 | $2,702 |
| Omeprazole | 145 | $2,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $539 | $118,80481 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $415 | $92,66769 claims |
| PfizerEliquis | $609 | $62,15864 claims |
| GSKArexvy, Arnuity Ellipta | $206 | $6,97328 claims |
| AstraZenecaSymbicort | $174 | $5,02123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Saint Louis
- Michael DonovanSaint Louis$78K
- Jarad SchwartzSaint Louis$36K
- Christina RobinsSaint Louis$27K
- Michael SpeziaSaint Louis$26K
- David GlickSaint Louis$17K
- Aaron BjornSaint Louis$16K
- Paul RutledgeSaint Louis$16K
- Melissa MurraySaint Louis$15K
- Robert PozziSaint Louis$15K
- Amy MillerSaint Louis$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.